Pelage Pharmaceuticals, a clinical-stage biotech developing a hair loss treatment, raised a $120 million Series B, CEO Daniel Gil tells Axios Pro.
Why it matters: The company says its hair growth product, if approved, would be the first androgenetic alopecia treatment cleared by the FDA since the 1990s.
